The baseline characteristics of REPOSE participants and the simulated cohort
| Characteristic | REPOSE trial population (n=260) | Simulated cohort (n=5000) |
| Continuous variables mean (SD) (% of individuals with data prior to imputation) | ||
| Baseline HbA1c (mmol/mol) | 76.0 (18.6) (100) | 75.9 (18.2) (100) |
| Baseline HbA1c (%) | 9.1 (1.7) (100) | 9.1 (1.7) (100) |
| Age (years) | 40.4 (13.4) (100) | 40.4 (13.3) (100) |
| Diabetes duration (years) | 18.0 (12.5) (100) | 18.0 (12.3) (100) |
| Triglycerides (mmol/mol) | 1.4 (1.0) (100) | 1.4 (0.9) (100) |
| Total cholesterol (mmol/mol) | 4.9 (0.9) (99.6) | 4.9 (0.9) (99.7) |
| HDL cholesterol (mmol/mol) | 1.6 (0.4) (96.5) | 1.6 (0.4) (96.4) |
| LDL cholesterol (mmol/mol) | 2.8 (0.9) (96.2) | 2.7 (0.9) (96.1) |
| Systolic blood pressure | 131.4 (16.4) (98.8) | 131.3 (16.0) (98.9) |
| Baseline cost of insulin | £357.24 (147.65) (94.8) | £360.39 (157.92) (98.4) |
| Baseline cost of diabetes-related contacts | £561.61 (885.92) (100) | £571.63 (928.92) (100) |
| Categorical variables n/N (percentage) (% of individuals prior to imputation) | ||
| Gender | ||
| Female | 104/260 (40.0) (40.0) | 1990/5000 (39.8) (39.3) |
| Male | 152/260 (58.5) (58.5) | 2950/5000 (59.0) (59.3) |
| Missing | 4/260 (1.5) (1.5) | 0/5000 (0.0) (1.4) |
| Physical activity | ||
| Low | 67/260 (25.8) (25.8) | 1266/5000 (25.3) (25.3) |
| Medium | 128/260 (49.2) (49.2) | 2471/5000 (49.4) (49.4) |
| High | 65/260 (25.0) (25.0) | 1263/5000 (25.3) (25.3) |
| Smoking status | ||
| Current | 50/260 (19.2) (19.2) | 951/5000 (19.2) (19.2) |
| Former | 67/260 (25.8) (25.8) | 1325/5000 (26.3) (26.3) |
| Never | 143/260 (55.0) (55.0) | 2724/5000 (54.5) (54.5) |
| Race | ||
| White | 258/260 (99.2) (99.2) | 4959/5000 (99.2) (99.2) |
| Black | 2/260 (0.8) (0.8) | 41/5000 (0.8) (0.8) |
| Nephropathy | ||
| No complications | 239/260 (91.9) (91.9) | 4600/5000 (92.0) (92.0) |
| Microalbuminuria | 13/260 (5.0) (5.0) | 234/5000 (4.7) (4.7) |
| Macroalbuminuria | 7/260 (2.7) (2.7) | 152/5000 (3.0) (3.0) |
| Dialysis or transplant | 1/260 (0.4) (0.4) | 14/5000 (0.4) (0.4) |
| Neuropathy | ||
| No complications | 238/260 (91.5) (91.5) | 4599/5000 (92.0) (92.0) |
| Neuropathy or ulcers | 22/260 (8.5) (8.5) | 401/5000 (8.0) (8.0) |
| Retinopathy | ||
| No complications | 145/260 (55.8) (55.8) | 28/5000 (56.0) (56.0) |
| Background diabetic retinopathy | 91/260 (35.0) (35.0) | 1740/5000 (34.8) (34.8) |
| Proliferative diabetic retinopathy | 24/260 (9.2) (9.2) | 465/5000 (9.3) (9.3) |
| Myocardial infarction | ||
| No complications | 255/260 (98.1) (98.1) | 4896/5000 (97.9) (97.9) |
| Myocardial infarction | 5/260 (1.9) (1.9) | 104/5000 (2.1) (2.1) |
| Stroke | ||
| No complications | 259/260 (99.6) (99.6) | 4983/5000 (99.7) (99.7) |
| Stroke | 1/260 (0.4) (0.4) | 17/5000 (0.3) (0.3) |
| Heart failure | ||
| No complications | 259/260 (99.6) (99.6) | 4934/5000 (99.6) (99.6) |
| Heart failure | 1/260 (0.4) (0.4) | 18/5000 (0.4) (0.4) |
| Angina | ||
| No complications | 257/260 (98.9) (98.9) | 4934/5000 (98.7) (98.7) |
| Angina | 3/260 (1.2) (1.2) | 66/5000 (1.3) (1.3) |
HDL, high-density lipoprotein; LDL, low-density lipoprotein; REPOSE, Relative Effectiveness of Pumps over Structured Education.